, the product inhibitor of the methylation reaction, with substituents that extend into the identified cavity, generated inhibitors that showed improved and selective activity against dengue virus methyltransferase (MTase), but not related human enzymes. Crystal structure of DENV MTase with a bound SAH derivative revealed that its N6-substituent bound in this cavity and induced conformation changes in residues lining the pocket. These findings demonstrate that one of the major hurdles for the development of methyltransferase-based therapeutics, namely selectivity for disease-related methyltransferases, can be overcome.
Methyltransferases (MTases) play key roles in normal physiology and human diseases through methylating DNA, RNA, and proteins. Almost all MTases use S-adenosyl-L-methionine (SAM) as a methyl donor and generate S-adenosyl-Lhomocysteine (SAH) as a by-product. Pharmacological modulation of MTases by small molecules represents a novel approach to therapeutic intervention in cancer and other diseases (1) . However, because the core domains of various MTases are conserved, designing inhibitors that specifically block the disease-related MTase without affecting other MTases, has been challenging. The ability to rationally design and generate selective inhibitors would have profound implications for development of new medicines for many methyltransferase-mediated diseases.
Dengue virus (DENV), from genus Flavivirus in the family Flaviviridae, is the most prevalent mosquito-borne viral pathogen that infects humans. The four serotypes of DENV (DENV-1 to -4) pose a public health threat to 2.5 billion people world-wide, and cause 50 to 100 million human infections each year. Neither vaccine nor antiviral therapy is currently available for DENV. The flavivirus MTase methylates the guanine N-7 and ribose 2'-O positions of the viral RNA cap in a sequential manner (i.e., GpppARNA→m7GpppA-RNA→m7GpppAm-RNA) (2, 3) . Recent studies have shown that flavivirus MTase is critical for viral replication and, therefore, represents a valid target for antiviral therapeutics (4, 5, 6) . We therefore examined the feasibility to design inhibitors that specifically modulate flavivirus MTase.
containing an N-terminal GST, were expressed in E. coli. BL21 cells and purified through a GSTPrep™ FF 16/10 column (GE Healthcare). The GST tag was then cleaved by thrombin and removed from the MTases using the GST column. The MTases were further purified through gel filtration to ensure protein purity was >95%. The proteins were then concentrated using Amicon Ultra tube (MW cut-off of 10KDa; Millipore).
Construction and analysis of mutant DENV-2-
DENV-2 (strain TSV01) genome-length cDNA clones with specific mutations were constructed by using an infectious cDNA clone pACYC FLTSV. The methods for mutagenesis of the cDNA clone, in vitro transcription, RNA transfection, immunofluorescence assay, and plaque assay were reported previously (7) .
Preparation of human RNA MTase (hRNMT)-
The 1st strand cDNA of hRNMT was synthesized using primer hRNMT-RT-REV (Supplementary  Table) and cellular RNA extracted from HuH7 cells. The cDNA encoding hRNMT amino acids 1-476 was PCR-amplified using primers hRNMTXho-FOR and hRNMT-Bam-REV (Supplementary  Table) from the RT reaction. The PCR product was cloned into expression vector pET15b (Novagen). The hRNMT protein, with an N-terminal His tag, was expressed in BL21 cells, and purified through a 5-ml HiTrap chelating HP column (Amersham Biosciences).
DENV MTase assays-Scintillation proximitybased N-7 and 2'-O methylation assays were used to determine the inhibitory activities of compounds, as previously reported (8, 9) . The standard deviation is calculated by the non-biased n-1 method: Indexing and scaling were performed using MOSFLM (12) and SCALA, part of the CCP4i suite (13) . The structures were determined by molecular replacement using MOLREP from the CCP4i package using DENV2 MTase (Pdb code 1L9K) (2) as a search probe. For the compound 10* structure, only one of the two molecules (molecule A) is bound to the inhibitor, whilst the other molecule C binds to the co-purifying SAH cofactor ( Table 2 ). The bond restraints for the compound were built using SKETCHER from the CCP4i package. Manual rebuilding of the model was performed using COOT (14) and the structures were refined using REFMAC5. The quality of the structures was analyzed using PROCHECK (15) .
Binding of RNA to DENV MTase measured by competitive fluorescence polarisation-To measure the displacement of GTP-bodipy binding to DENV MTase by RNA, we adapted the method used by (17) . Briefly, 100 nM GTP-bodipy and 300 nM MTase in 50 mM Tris/HCl pH 7.5 plus 20 mM NaCl were incubated with two-fold serial dilutions of RNA ranging from 0-3 μM in black 96-well ½ area microplate (Corning). Fluorescence polarization was measured using Synergy 4 microplate reader (Biotek, USA) with λ ex = 485 nm and λ em = 528 nm. IC 50 (concentration of ligand needed to displace 50% of GTP-bodipy) was determined by fitting the dose response curve with: K i for ligand was defined by the Cheng-Prusoff equation (11):
where K d is the dissociation constant of GTPbodipy for MTase (K d = 0.8 ± 0.2µM).
Thermo-denaturation assay-Three µM of MTase were incubated with 0.01X SYPRO ® Orange protein gel stain (Invitrogen) in the absence or presence of 50 µM sinefungin (SF) in 1× assay buffer (50 mM Bis/Tris-HCl pH7.5 and 20 mM NaCl) for 10 min in a 96-well PCR white plate (Bio-Rad, Hercules, USA). The plate was then sealed with Microseal ® B Adhesive sealer (Bio-Rad, Hercules, USA) and heated from 25°C to 85°C with increments of 0.5°C using iQ ™ 5 Multicolor RealTime PCR Detection System (Bio-Rad, Hercules, USA). Excitation and emission wavelengths were 485 nm and 625 nm respectively. MTase melting temperature (Tm) in the presence or absence of SF was determined from the graph of -dRFU/dT versus temperature, where RFU is relative fluorescence unit and T is the temperature in degree Celsius.
RESULTS

DENV
MTase-SAM co-crystal complex-We determined the crystal structure of DENV-3 MTase (representing the N-terminal 272 amino acids of the viral NS5 protein) in complex with methyl donor SAM at a resolution of 1.7 Å (PDB code 3P8Z), with a final Rfactor of 19.2% and an Rfree of 22% ( Fig. 1 ; Tables 1 and 2 ). The structure of the SAM-MTase complex is almost identical to that of the SAH-MTase complex (2), with an overall Cα root-mean-square deviation (rmsd) of 0.49 Å (Fig. 1A) . The current structure also closely resembles MTase structures from other members of the Flavivirus family (reviewed in 18). All residues forming the SAM/SAH-binding pocket are well superimposed (data not shown), indicating that the extra methyl group in the SAM molecule does not affect the ligand-protein interaction. Since no SAM was present during the crystallization, its presence in the structure must have originated from E. coli. during protein expression. Biochemical analysis of the purified MTase also suggested that the SAM molecule was co-purified with the protein (Supplementary Fig. 1 ).
Mutation of residues lining the hydrophobic pocket affect virus replicationStructure examination located the additional hydrophobic cavity (colored in yellow, Fig. 1B ) above the adenine base that was previously identified in West Nile virus (WNV) MTase (19) . As shown in Fig. 1C , the cavity is lined by the conserved amino acids F133, I147, G148, E149, R160, R163, V164, and L182, among which F133 and I147 also contribute to the SAM-binding pocket. Functional analysis of the identified cavity was performed through Ala mutations of these residues in the context of genome-length RNA of DENV-2. After transfection into BHK-21 cells, wild-type (WT) and mutant RNAs generated varying amounts of envelope protein-expressing cells in the order of WT>F133A≈L182A >G148A>R163A>R160A ( Fig. 2A) . All RNAs produced infectious viruses with plaque sizes of WT≈F133A≈L182A>G148A≈R163A>R160A (Fig.  2B ). Sequencing analysis showed that all mutant viruses retained the engineered changes with no other mutations (data not shown). The growth kinetics of F133A and L182A viruses was similar to that of WT virus, whereas the G148A, R160A, and R163A viruses replicated slower than the WT virus (Fig. 2C) . At 24 h post-infection, the viral titers of these latter three mutant viruses were about 1,000-fold less than that of WT virus (Fig. 2C) . Similar results were obtained from three independent transfection experiments. The negative effect of the R160A or R163A substitution on viral replication was further confirmed using a luciferase-reporting replicon ( Supplementary Fig.  2 ). In vitro enzymatic assays using recombinant MTases ( Supplementary Fig. 3 ) showed that most of the mutations reduced either N-7 (R160A, R163A) or 2'-O (F133A, L182A) methylation activities, whilst both activities were significantly decreased in mutant G148A (Table 3) . Thermodenaturation analysis suggests that the defects in cap methylations are not due to mis-folding of the mutant MTases as their melting temperatures are not significantly reduced compared to the WT protein. In addition, their ability to bind RNA and sinefungin was not markedly different from WT protein (Table 3) . Overall, the data supports results obtained with WNV that the identified cavity is important for Flavivirus cap methylations as well as replication in cells (19) .
Design and synthesis of selective inhibitors of flavivirus MTase-The structural and functional results prompted us to design inhibitors that can specifically bind to the identified cavity of the flavivirus MTase. Since this cavity connects to the SAM-binding pocket at the adenineholding site, we postulated that substituents extending from the adenine base of the SAH molecule would interact with the identified cavity. Such SAH derivatives would have the potential to selectively inhibit DENV MTase without suppressing host MTases. To test this hypothesis, we synthesized a series of SAH analogs, each with a substitution at the N-6 position of the adenine base (Fig. 3) . This N-6 position was selected for two reasons: (i) It is in the most optimal geometrical position for making extensions to occupy the hydrophobic cavity, and (ii) the N-6 is the most chemically tractable group in the adenine ring for modifications. Compound synthesis was detailed in Supplementary Materials. The compounds were assayed as inhibitors of N-7 and 2'-O methyltransferase activities using DENV-3 MTase. For ease of synthesis, initial structureactivity relationship (SAR) was assessed with compounds synthesized as epimeric mixtures, except for compounds 1* and 3* (Symbol "*" indicates enantiopure; Table 4 ). The SAR showed that, compared with SAH, a substitution with small alkyl groups (compounds 1* and 2) or a phenyl ring (compound 3*) reduced the anti-MTase activity. Further extension of the substituent showed that a benzyl group was optimal (compound 4), retaining the activity of SAH. Lengthening the spacer by one carbon between the phenyl ring and the adenine N-6 reduced the activity (compound 5). Addition of a methyl group on the aryl ring at different positions indicated that the meta position is optimal, leading to an increase in potency of almost 4-fold over the starting point (compare compound 7 with 6 and 8). Next, halogen substituents were introduced at the meta position (compounds 9-12); these compounds exhibited potencies similar to the methylsubstituent analog (compound 7). Compared with the SAH starting point, compounds 7 and 9-12 consistently showed better potencies; this conclusion was further supported by the results from enantiopure compounds 10* and SAH* (Table 5 ). For each compound, the K i value for N-7 methylation was higher than that for 2'-O methylation; this difference could result from the distinct mechanisms of the two cap methylations (20, 21) . The parent compound, SAH*, also displayed similar differences in N7 and 2'-O inhibition. Nonetheless, the general SAR trend was the same in N-7 and 2'-O methyltransferase activities. In stark contrast to SAH and compounds 1-3, the compounds with extended phenyl rings (compounds 4 and 5), and N-6 benzylic substituents (compounds 6-12) had either partially or completely lost the activity against human RNA guanine-7-MTase (hRNMT), DNA MTase 1A (hDNMT1A ; Tables 4 & 5) , and SET7/9 histone methyltransferases (hHMT; data not shown). These results demonstrate that the N-6 modified SAH derivatives can selectively inhibit DENV MTase.
Since the identified cavity is conserved among flavivirus MTases, we examined whether the SAH analogs would inhibit flavivirus MTase other than DENV. As shown in Table 5 , compound 10* also inhibited WNV MTase but was about 2.2-fold less potent than SAH*. Nevertheless, compound 10* did not inhibit host hRNMT or hDNMT (Table 5) , indicating its selectivity for flavivirus MTase.
Crystal structure of DENV-3 MTase-compound complex-To provide structural evidence for mode-of-action, we solved the crystal structure of DENV-3 MTase in complex with compound 10* at a resolution of 1.7 Å (PDB code 3P97; Table 1 and 2). The overall structure of the compound 10*-MTase complex is almost identical to that of the SAM-MTase complex, with a Cα rmsd of 0.16 Å (Fig. 4A) . As shown in Figs. 4A & 4B, the N-6 benzyl ring of compound 10* fits snugly into the identified cavity without changing the binding of the SAH moiety. Remarkably, the benzyl ring of the compound induces a local conformational change within the cavity (Figs. 4C & 4D) : the side chains of F133 flips away from the cavity by 100 degrees (measured at the Cα and Cβ torsion angle) to create space for the N-6 benzylic ring, and the side chains of R163 shifted by 3.5 Å (measured at the NH1 atom) to stack onto the benzylic ring, resulting in the formation of a cation-π interaction. Fig. 4E summarizes the interactions established between compound 10* and the DENV-3 MTase.
Effect
of compound-induced conformational change on efficacy-The observed flipping of F133 in the co-crystal structure of DENV-3 MTase-compound complex suggests that this residue at its native conformation sterically blocks the binding of the N-6 benzylic ring. If this is the case, substitution of F133 to a residue with a smaller side chain would facilitate the binding of the benzylic ring of compound 10*; consequently, the mutant MTase would be more sensitive than the WT MTase to compound inhibition. To test this hypothesis, we prepared a mutant MTase containing a Phe→Ala substitution at amino acid position 133. Indeed, the K i values of the F133A MTase were lower (120-fold for N-7 activity and 11-fold for 2'-O activity) than that of the WT MTase (Table 5 ). These results demonstrate that the selective inhibition of compound 10* against DENV MTase is obtained through binding of the N-6 benzylic ring to the identified pocket.
DISCUSSION
We used DENV MTase as a model to prove the concept that selective inhibitors of disease-related MTase could be obtained. The selectivity was accomplished through designing SAH derivatives with substituents in the adenine moiety that extend into a cavity located above the SAM binding pocket. The newly identified pocket is unique to the flavivirus MTases (18, 19) and was not found in the crystal structures of several human MTases available in the Protein Data Bank (data not shown). The starting compound, SAH, is a well-known product inhibitor, which is nonselective and inhibits eukaryotic, bacterial, and viral MTases (22) (23) (24) . In our hands, it showed similar inhibitory properties against DENV, WNV, human RNA, DNA and histone MTases (data not shown). Attachment of small alky or phenyl groups to the N6-position in its adenine base failed to improve its potency against DENV MTase or hRNMT, but moderately enhanced its activity against hDNMT by 2-3-fold. Our findings contradicts a previous report in which compound 3 was found to be inactive against hDNMT (25) . Introduction of a benzyl ring retained its activity against DENV MTase and strongly reduced its activity against hRNMT. No activity was observed against hDNMT. Thus, some gain in selectivity for DENV MTase was possible through this modification. This result is in agreement with the hDNMT data obtained by Saavedra et al. (25) . Extension of the benzyl group with a second carbon chain significantly reduced inhibition against all enzymes tested. It is possible that the hydrophobic pocket does not accommodate this longer extension; alternatively, the loss of activity may be due to greater flexibility of the carbon linker and resultant poorer binding into the cavity. Further probing with substituents in the aryl ring revealed that additions in the meta-position provided moderate improved potency for DENV MTase but gained selectivity against hRNMT, DNMT and histone MTases (data not shown). Substitution with either a methyl-, chloro-or fluoro-group in the meta-position resulted in about 4-fold better inhibitory properties compared to SAH. Replacement of a bromo-or iodo-group in this position exhibited similar inhibitory properties on DENV MTase, as the un-substituted aryl ring, indicating that bulky groups on the aryl ring were not preferred. On the other hand, substitution in the ortho-position was not advantageous, whilst the para-position conferred some improvement against DENV N7-activity only. Remarkably, additions in all three positions rendered the compounds either inactive or poorly active against hRNMT, hDNMT and hHMT (data not shown).
Residue F133 is conserved in the several mosquito-and tick-borne Flaviviruses, including DENV, WNV and JEV (19) . Mutation of this amino acid to Ala did not affect DENV N7 and 2'-O activity in vitro, nor impaired DENV growth in cells. Thus, this residue is not critical for virus replication. Furthermore, F133 is rather flexible, as binding of compound 10* in DENV MTase induced its side chain to rotate away from the cavity, to accommodate its N6-substituted aryl ring. It is possible that other residues lining the pocket may have similar mobilities. Indeed, the improved potency of compound 10* over SAH* can be partially explained by the movement of residue R163, to form a strong cation-π interaction with the N6-aryl ring of compound 10*.
Although the benzyl-SAH derivatives were selective for both DENV and WNV MTases, confirming the importance of the hydrophobic pocket (19) , the most active compound, 10*, was not more potent in WNV compared to SAH*. Detailed examination of the hydrophobic pockets in both MTases did not reveal any obvious difference between the two sites, and the reason for the discrepancy in the potency of the compounds for the two virus enzymes is unknown. Nevertheless, both SAH* and compound 10* are significantly more potent on WNV 2'-O activity compared to the same activity in DENV (14 and 18-fold better, respectively, in WNV). In contrast, the opposite is true for their N7 activities. Both compounds respectively, showed 4-and 24-fold less potency in WNV than DENV. Thus, the observed difference in the two viral MTases for this class of compounds may be related to variations in their N7 and 2'-O mechanisms (20, 21) .
In summary, using a structure-guided approach, we have designed DENV selective and potent inhibitors by taking advantage of a specific pocket found in Flavivirus MTases, and provided a paradigm that may facilitate pharmacological therapeutics targeting other disease-related MTases. 
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